Adamis Pharmaceuticals (ADMP) PT Set at $5.00 by Maxim Group

Adamis Pharmaceuticals (NASDAQ:ADMP) has been assigned a $5.00 price objective by Maxim Group in a report issued on Wednesday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Maxim Group’s price objective would suggest a potential upside of 38.89% from the stock’s current price.

The analysts wrote, “We have not had any recent news on the launch and other developments associated with Symjepi. As a result, we are increasing our therapeutics risk cut to 30%, from 25%, in our Epinephrine Pre-Filled syringe model, commercial assumptions. In addition, we are also pushing-out our timing back for the other” pipeline products models which include APC-1000, APC-2000 and APC-5000 inhalers. The result of these changes is our price target falls to $5, from $14.””

A number of other equities analysts also recently weighed in on ADMP. Zacks Investment Research upgraded Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. B. Riley set a $10.00 target price on Adamis Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, November 30th. Finally, ValuEngine downgraded Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 30th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $7.33.

Shares of Adamis Pharmaceuticals (NASDAQ:ADMP) traded down $0.03 on Wednesday, hitting $3.60. The stock had a trading volume of 349,600 shares, compared to its average volume of 572,545. The firm has a market cap of $114.85, a P/E ratio of -4.91 and a beta of 0.19. Adamis Pharmaceuticals has a one year low of $3.20 and a one year high of $6.45. The company has a quick ratio of 3.79, a current ratio of 3.93 and a debt-to-equity ratio of 0.06.

Several institutional investors and hedge funds have recently modified their holdings of ADMP. B. Riley Financial Inc. acquired a new position in shares of Adamis Pharmaceuticals in the 4th quarter valued at about $1,022,000. Vanguard Group Inc. grew its stake in shares of Adamis Pharmaceuticals by 22.2% in the 2nd quarter. Vanguard Group Inc. now owns 942,940 shares of the specialty pharmaceutical company’s stock valued at $4,903,000 after buying an additional 171,167 shares in the last quarter. EAM Investors LLC grew its stake in shares of Adamis Pharmaceuticals by 58.3% in the 3rd quarter. EAM Investors LLC now owns 371,732 shares of the specialty pharmaceutical company’s stock valued at $1,942,000 after buying an additional 136,970 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Adamis Pharmaceuticals in the 4th quarter valued at approximately $442,000. Finally, Granite Investment Partners LLC bought a new stake in shares of Adamis Pharmaceuticals in the 3rd quarter valued at approximately $457,000. Institutional investors own 16.54% of the company’s stock.

WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/02/14/adamis-pharmaceuticals-admp-given-a-5-00-price-target-at-maxim-group.html.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply